Skip to main content

1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU; Carmustine) Polymer Wafer (Gliadel)

  • Chapter
  • First Online:
Neuroimaging Pharmacopoeia
  • 1120 Accesses

Abstract

Carmustine was one of the first systemic chemotherapies to gain FDA approval for the treatment of brain tumors. More recently, carmustine-infused polymer wafers have been used to deliver locally higher doses of chemotherapy directly to the surgical tumor bed while obviating systemic side effects, such as myelosuppression and pulmonary toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  • Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887–93.

    Article  PubMed  Google Scholar 

  • Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol. 2000;53(5):458–64.

    Article  CAS  PubMed  Google Scholar 

  • Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, Tonn JC, Hilt D, Westphal M. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol. 2004;66(3):351–60.

    Article  PubMed  Google Scholar 

  • Nagpal S. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. Neurosurg Clin N Am. 2012;23(2):289–95, ix.

    Article  PubMed  Google Scholar 

  • Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, Kesari S, Dörner L. Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro Oncol. 2012;14(4):482–90.

    Article  PubMed Central  PubMed  Google Scholar 

  • Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel Thomas Ginat MD, MS .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ginat, D.T. (2015). 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU; Carmustine) Polymer Wafer (Gliadel). In: Ginat, D., Small, J., Schaefer, P. (eds) Neuroimaging Pharmacopoeia. Springer, Cham. https://doi.org/10.1007/978-3-319-12715-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12715-6_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12714-9

  • Online ISBN: 978-3-319-12715-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics